Table 1.
List of selected miRNAs and their clinical association
| miRNA | Disease | Clinical association | References |
|---|---|---|---|
| miR-142-3p (↑) | Systemic sclerosis | Severity of disease | Makino et al. 2011 |
| miR-155 (↑), miR-146a (↑), miR-132 (↑), and miR-16(↑) | Rheumatoid arthritis | Pathogenesis of disease | Pauley et al. 2008 |
| miR-9 (↑), miR-29a (↑), miR-30d (↑), miR-34a (↑), miR-124a (↑), miR-146a (↑) and miR-375 (↑) | Newly diagnosed type 2 diabetic | Pathogenesis of disease | Kong et al. 2011 |
| miR-103 (↑), miR-107 (↑), miR-155(↓), miR-21(↑) | Pancreatic cancer | Distinguish tumors with different clinical behavior | Roldo et al. 2006 |
| miR-150 (↓) | Pancreatic cancer | Pathogenesis of disease | Srivastava et al. 2011 |
| miR-141 (↑) | Prostate cancer | Distinguish cancer patients from healthy ones | Mitchell et al. 2008 |
| miR-146a (↓) | Prostate cancer | Development of hormone refractory prostate cancer | Lin et al. 2008 |
| miR-10b (↑) | Prostate cancer | Biochemical relapse of disease | Fendler et al. 2011 |
| miR-10b (↑) | Pancreatic cancer | Aggresive behavior of disease and poor survival of patient | Nakata et al. 2011 |
| miR-451 (↓) | Gastric cancer | Survival of patient | Bandres et al. 2009 |
| miR-34a (↓) | Chronic lymphocytic leukemia | Drug resistance | Zenz et al. 2008 |
| miR-196a (↓) | Barrett’s esophageal metaplasia-dysplasia-invasive adenocarcinoma | Disease progression | Maru et al. 2009 |
| miR-122 (↓) | Hepatocellular carcinoma | Metastatic behavior of disease | Coulouarn et al. 2009 |
| miR-145 (↓), miR-21(↑), miR-129 (↑) | Bladder cancer | Disease progression | Dyrskjot et al. 2009 |
| miR-221 (↓) | Prostate cancer | Aggressive and metastatic behavior and disease | Spahn et al. 2010 |
(↑) Up regulated; (↓) Down regulated